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Surveillance of antibiotic susceptibility of Neisseria
gonorrhoeae in the WHO Western Pacific Region
1992-4
WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme*
Objective: To describe the establishment and outcomes of a regional programme of continuing
long term surveillance of antibiotic susceptibility of Neisseria gonorrhoeae over the period 1992-4.
Methods: Laboratories in 17 countries in the WHO Western Pacific Region participated in a
continuing programme of surveillance of the susceptibility of gonococci to an agreed group of
antibiotics over 3 years. Established techniques were used and these included quality control
and proficiency testing systems.
Results: About 20 000 gonococci were examined over a 3 year period. Resistance to the peni-
cillins through P lactamase production or chromosomal mechanisms was widespread, with fur-
ther changes evident over the 3 years. Spectinomycin resistance was infrequently encountered
but high level tetracycline resistance was present in most participating centres, with some having
high proportions of tetracycline resistant organisms. Quinolone resistance increased and became
widespread throughout the region in the 3 years, ultimately involving all but one centre. Both
the number and minimum inhibitory concentrations of quinolone resistant isolates increased
markedly.
Conclusions: Patterns of gonococcal resistance to antibiotics continue to evolve, at times
rapidly, and have the potential for wide and rapid dissemination. Regional surveillance pro-
grammes can be developed by using and expanding existing resources. Data thus derived were
applied to the development of appropriate treatment regimens in the region, and emphasised
further the need for a global expansion of the programme of integrated surveillance of gonococ-
cal resistance.
(Genitourin Med 1997;73:355-361)
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Recent WHO estimates put the number of
new cases of gonorrhoea worldwide at 62 mil-
lion annually.' The same sources indicate that
the significant morbidity that often accompa-
nies gonococcal disease can be greatly reduced
by appropriate treatment. For example, for
every 100 women with gonorrhoea (25% preg-
nant) properly treated, 25 cases of pelvic
inflammatory disease, one ectopic pregnancy,
six cases of infertility, and seven instances of
ophthalmia neonatorum are said to be pre-
vented.'
Additionally, it is now acknowledged that
gonorrhoea (along with other non-ulcerative
STDs) is a potent cofactor in the transmission
of the human immunodeficiency virus
(HIV).2A The "synergy between HIV and
STDs is related to both behavioural and bio-
logical factors"3 and it has been shown in lon-
gitudinal studies that the rate of transmission
of HIV may be amplified by a factor of
between three and five in the presence of gon-
orrhoea.4 The converse of this situation is that
better STD treatment, and through it a reduc-
tion in the prevalence of STDs, can contribute
to a reduction in HIV transmission.5 In a pop-
ulation with a high prevalence of HIV infec-
tion, effective treatment of 100 cases of
gonorrhoea in core groups leads to a cumula-
tive reduction of 425 cases of HIV transmis-
sion over a 10 year period.' STD prevention
and treatment are thus increasingly regarded
as an important component of HIV preven-
tion.6
Therefore, there are clearer and more
cogent reasons than ever before to ensure that
gonococcal disease is properly treated when it
cannot be otherwise prevented.7 The essential
point about such treatment is that it must be
effective, and for gonorrhoea this means use of
an appropriate antibiotic treatment regimen,
preferably single dose. Limiting factors in the
provision of this appropriate antibiotic treat-
ment are the continuing emergence of antibi-
otic resistance in the gonococcus and the
current distribution of the disease which
affects most often patients in resource poor
settings where many recommended regimens
are unavailable or else too costly.
One strategy adopted by the WHO to
obtain information on gonococcal susceptibil-
ity patterns and thereby implement appropri-
ate and proper treatment has been to establish
a global surveillance network to monitor
antibiotic resistance in the gonococcus-the
Gonococcal Antimicrobial Surveillance
Programme (GASP). This was envisaged as a
series of networks in the various WHO
regions. The GASP network was to gather
data on gonococcal resistance patterns in dif-
ferent countries and make this information
available for implementation of effective treat-
ment regimens at global, regional, or national
levels.5 It was also envisaged that there would
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expertise by the network and early identifica-
tion of new forms of gonococcal resistance
with control measures recommended.8 The
relevance of surveillance of antibiotic resis-
tance in gonococci to treatment has been
recently reviewed.9 Factors which have ham-
pered the full implementation of the GASP
network include the same limitations in provi-
sion of technical resources in less developed
nations that restrict access to antibiotics in
these settings. None the less, GASP has func-
tioned in the WHO Western Pacific Region
(WPRO) since 1992 and is also operating in
North and South America and in the WHO
South East Asian region more recently. This
paper describes the establishment and struc-
ture of the WPRO GASP and documents its
findings over the years 1992 to 1994. The
wider implications of the emergence of antibi-
otic resistance in the gonococcus in WPRO are
discussed.
Materials and methods
ESTABLISHMENT OF THE PROGRAMME
The programme was established under the
auspices of the WHO Western Pacific
Regional Office (WHO WPRO) to contribute
to the aims and objectives of the global GASP
network (see above8) through continuing long
term antibiotic susceptibility surveillance in
the region.'0 It was instituted as a distinct sub-
set of a wider programme of antimicrobial
resistance surveillance following a meeting of
WPRO country representatives (designated as
"focal points") in Hong Kong in December
1991.10 Seventeen centres in the WHO WPRO
have participated as focal points in the pro-
gramme since 1992-Australia, Brunei,
China, Fiji, Hong Kong, Japan, Malaysia,
New Caledonia, New Zealand, Papua New
Guinea, Philippines, Singapore, Solomon
Islands, South Korea, Tonga, Vanuatu, and
Vietnam. Some of these centres represented
relatively small geographic areas-for exam-
ple, Singapore and Hong Kong, while other
centres were already focal points for collection
of data from wider sources in their own coun-
tries. For example, Australia" 12 and China
had an existing networked system of laborato-
ries, and Malaysia had laboratories serving
STD clinics in different geographic areas of
the country which referred a standard sample
of their isolates for testing in the central labo-
ratory.
POPULATION AND ISOLATE SELECTION
A description of the patient population from
which isolates were derived was requested
from all participants-namely, unselected
STD patients-that is, patients presenting for
treatment with signs and symptoms; screen-
ing/case finding; or unknown. Similarly, par-
ticipants were asked to record if all or a sample
of isolates were tested.
ANTIBIOTIC SUSCEPTIBILITY DETERMINATION
A core list of antibiotics for testing, based on
WHO recommended treatments, was agreed.
Testing for P lactamase (by acidometric or
chromogenic cephalosporin techniques nomi-
nated by the WH'013) was the minimum
requirement for entry into the project. Two
methods of testing for chromosomal resistance
to the penicillins and for resistance to the
other core antimicrobials were nominated.
These were the disc, agar inclusion break-
point, or agar inclusion minimum inhibitory
concentration (MIC) techniques of the
NCCLS'4 15 and the AGSP," both used exten-
sively in the region.
VALIDATION OF RESULTS
WHO reference cultures A-E with assigned
sensitivity categories were distributed to all
participants together with a comprehensive
methodological manual providing details of
categorisation of "wild" strains by the zone
sizes/MICs obtained with the different meth-
ods. These values were verified in the refer-
ence laboratory for the two nominated
methods. The reference cultures were used in
quality control (QC) procedures and were to
be incorporated regularly when batches of wild
type isolates were examined. Additionally in
each year of the project, a series of six quality
assurance (QA) strains were distributed as
"unknowns" to each centre for examination.
Again these strains were first examined in the
reference laboratory and catergorised on the
basis of testing by the two nominated meth-
ods. Results of examination of the reference
QC and the QA strains were forwarded to the
reference laboratory. The QA isolates were
specifically chosen to reflect the resistance pat-
terns seen in gonococci isolated in the region
and were selected on the basis of MIC/clinical
outcome correlates. 16 Assesment of laboratory
performance was based on previously estab-
lished factors.'2 Each laboratory was appraised
of its own results but group QA reports did
not identify individual participants.
COLLATION OF DATA
Results were recorded on standard data pro-
cessing forms and returned periodically
throughout each year to the regional reference
laboratory at the Prince of Wales Hospital in
Sydney. Because of the limitations in
resources in some settings, the standard
reporting forms were in a summary format
which separately recorded the category of sus-
ceptibility of each isolate to each antibiotic,
but did not seek to record multiple antibiotic
susceptibility/resistance in individual isolates.
An additional data recording sheet was avail-
able to record this further information but was
not used in all centres. Data were summarised
and annual reports were prepared, pub-
lished'7 18 and distributed after examination
and agreement by participants. Significance
tests were performed by X2 analysis.
Results
DEMOGRAPHIC DATA
A total of 20 365 isolates was examined in the
17 WHO WPRO participating centres in the
years 1992-4 inclusive. However, the number
of isolates and the number of centres reporting
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differed in each of the 3 years. In 1992, 5872
isolates were examined in 14 centres, in 1993,
7176 isolates in 16 centres were available, and
7317 isolates were tested in 16 centres in
1994. Each centre participated for at least 2 of
the 3 years. In some centres the number of iso-
lates examined was substantial. However, it
was not possible to estimate for each country
the proportion of all cases of gonorrhoea that
this examination represented. Large or moder-
ate numbers of isolates were examined in
Australia, China, Fiji, Hong Kong, Korea,
Malaysia, New Zealand, Papua New Guinea,
Singapore, and Vietnam. In other centres,
such as Japan, only a few isolates were avail-
able for routine examination. In the Pacific
Island states facilities for culture often exist
only in the larger population centres of some
countries-for example, the Solomon Islands.
In some countries (Australia, China, and
Malaysia) the strains were drawn from a wide
geographic base by means of existing net-
works. Other countries such as Hong Kong
and Singapore obtained a large number of
strains from a small geographic area. Other
centres were limited in their access to strains
(Philippines) or confined to the same certain
parts of the country over the period studied
(Korea, Vietnam) or else only had a few iso-
lates but examined them all (New Caledonia).
Most strains examined in the participating
centres were isolated from unselected sympto-
matic STD clinic patients although in the
Philippines isolates were obtained as a result
of case finding. In all focal points the source of
isolates remained relatively constant over the
period of the study.
Some centres determined the susceptibility
of all or most of the available isolates to all
antibiotics (Australia, Fiji) whereas others
examined a systematic sample (Malaysia) or
else only examined antibiotics pertinent to
their situation or resources. In Singapore,
while all isolates were examined for P lacta-
mase production in 1992, MIC testing of a
systematic sample of these strains was only
commenced in the second half of that year.
Tables 1-5 provide details of the resistance to
the nominated "core" antimicrobials peni-
cillin, quinolones, spectinomycin, and tetracy-
cline (high level only) resistance in the
contributing centres in the years 1992-4 inclu-
sive, and the number of isolates examined for
susceptibility to each of these antibiotics and
to ceftriaxone in each centre. Data from all
centres are aggregated into a single figure for
each country in the tables. In some of the geo-
graphically larger centres-for example,
Australia, regional variation in sensitivity
within the country was evident. Where this is
significant it is specifically mentioned.
SUSCEPTIBILITY TO THE PENICILLINS
Resistance to the penicillins was widespread
throughout the region (table 1) with only two
centres (New Caledonia and Vanuatu) having
little or no resistance on a country based
analysis. Within Australia there were consider-
able differences between the larger urban cen-
tres with high rates of resistance and rural
areas where penicilllin based therapy remained
effective. Plasmid mediated P lactamase resis-
tance (by penicillinase producing Neisseria
gonorrhoeae, PPNG) was particularly evident
in Korea, the Philippines, Malaysia,
Singapore, and Vietnam. Of interest is the
Table 1 Percentage oflactamase mediated, chromosomally mediated, and total penicillin resistance in gonococci in 17
WPRO GASP centres, 1992-4. (Number of strains tested are shown in parentheses)
1992 1993 1994





























































































55 0 55 64-6










































































































































BLR = penicillinase producing gonococci;
plus chromosomal resistance.
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Table 2 Percentage ofgonococcal isolates showing altered quinolone sensitivity in 14 WPRO GASP centres, 1992-4
1992 1993 1994
Country Tested % LS % Res Tested % LS % Res Tested % LS % Res
Australia 782 2-9 0-13 1570 2-7 0-001 1622 1-4 0.4
Brunei 20 0 0 40 6-6 0
Fiji 0 24 0 0 804 0-1 0
Hong Kong 0 0 1664 55.9 3-3
Japan 104 21 1.9 53 45-2 3-7 79 35-4 2-5
Korea 43 9 0 225 12 0 192 25 0
Malaysia 185 0 0 280 0-1 0 148 1-4 0
New Caledonia 46 6-5 0 18 0 0 16 6-2 0
NewZealand 12 0 0 85 1.1 0 127 2-4 1-6
Papua New
Guinea 0 40 12-5 0 218 0 5
Philippines 0 0 20 95
Singapore 0 611 2.8 0.33 667 11-2 1-8
Solomon Islands 0 15 0 0 20 0 0
Vietnam 19 0 0 116 2-6 0 218 4-6 6-9
LS = less sensitive; Res = resistant.
increase in PPNG in China and Vietnam over
the 3 year period (p < 0.05) and the decline in
numbers of PPNG in Hong Kong. Also of
interest was the presence of PPNG in increas-
ing numbers in some Pacific Island states with
high proportions of PPNG in Tonga and the
Solomon Islands. Chromosomally mediated
penicillin resistant Neisseria gonorrhoeae
(CMRNG) was also widespread in the region.
While the true extent of this phenomenon is
difficult to estimate in the presence of PPNG
and can only be properly determined by repeat
testing of strains after plasmid curing,19 suffi-
cient data are available to suggest that this was
also a considerable problem in the region but
with differences apparent in the various cen-
tres.
SUSCEPTIBILITY TO THE QUINOLONES
A considerable increase in quinolone resis-
tance was observed during the 3 year period
surveyed (table 2). In 1992, 1211 strains were
tested. In Japan there was a significant propor-
tion of isolates (21 %) with low level resistance
to quinolone antibiotics. A low prevalence of
low level resistance to the quinolones was also
observed in two of the other seven centres test-
ing these agents (Australia and New
Caledonia). Fully developed high level resis-
tance was seen in only a few isolates in Japan
and Australia. In 1993, an additional four cen-
tres undertook this examination and a total of
3077 isolates were examined. Low level resis-
tance was present in nine of the 12 centres
with again a high proportion of isolates from
Japan exhibiting this phenomenon.
Additionally Japan, Singapore, and Australia
now reported high level resistance, although
again at a low frequency. In 1994, 13 centres
tested 5795 strains for quinolone resistance
and all but one (Solomon Islands) noted the
presence of some form of resistance, some in a
very high proportion of isolates examined
(Hong Kong, Korea, Japan, Philippines). High
level quinolone resistance was present in seven
of the 13 centres and in higher proportions
than previously recorded. In addition to the
high number of resistant isolates observed in
Hong Kong and the Philippines in 1994, sta-
tistically significant increases (p < 0.05) were
observed in the numbers of quinolone resis-
tant isolates in separate data from Japan,
Korea, Singapore, and Vietnam over the
period of the study.
SUSCEPTIBILITY TO SPECTINOMYCIN
Examinations for spectinomycin resistance
were performed in 13 centres in the 3 years
(table 3). The number of strains tested
increased from 1440 in eight centres in 1992
to 3687 isolates in 11 centres in 1994.
Resistance was consistently seen only in a
small proportion of strains in Papua New
Guinea and China, the latter observation con-
firming a prior finding.20 Sporadic instances of
in vitro resistance to spectinomycin were also
seen in New Caledonia, Vietnam, and
Australia. Specifically, no resistance was seen
in 53 isolates in Korea in 1994.
HIGH LEVEL TETRACYCLINE RESISTANCE
High level tetracycline resistant Neisseria gon-
orrhoeae (TRNG) were also present in the
region (table 4), with Singapore and Malaysia
consistently having a high proportion of iso-
lates with this form of resistance. No TRNG
Table 3 Percentage ofgonococcal isolates resistant to spectinomycin in 13 WPRO GASP centres, 1992-4
1992 1993 1994
Country Tested % Resistant Tested % Resistant Tested % Resistant
Australia 782 0 1570 0 1622 0-06
Brunei 20 0 40 0 0
China 109 12-8 638 1.4 343 5 3
Fiji 0 0 399 0
Hong Kong 0 1041 0 0
Japan 149 0 32 0 26 0
Korea 0 0 53 0
Malaysia 185 0 280 0 296 0
New Caledonia 46 0 18 5-5 16 0
Papua New Guinea 0 30 3 3 57 1-8
Singapore 130 0 568 0 667 0
Solomon Islands 0 15 0 20 0
Vietnam 19 0 58 0 188 0.5
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Table 4 Percentage of isolates showing high level tetracycline resistance (TRNG) in 15 WPRO GASP centres, 1992-4
1992 1993 1994
Country Tested % TRNG Tested % TRNG Tested % TRNG
Australia 782 2-3 1570 2-7 1622 4-1
Brunei 20 0 0 0
China 117 15-4 0 287 8
Fiji 848 0.4 593 0.3 804 0-1
Japan 148 0 49 2 26 0
Korea 43 2-3 225 8 192 1-5
Malaysia 185 31 280 38-9 148 49.3
New Caledonia 46 8-7 18 0 16 6-2
New Zealand 12 0 85 0 127 3-1
Papua New Guinea 0 40 7-5 218 4-1
Philippines 59 22 0 0 20 100
Singapore 130 43-8 769 38-1 667 47-1
Solomon Islands 0 15 0 20 0
Tonga 32 0 0 0
Vietnam 41 7-3 157 17-1 220 83-6
TRNG = tetracycline resistant Neisseria gonorrhoeae.
were detected in Brunei, the Solomon Islands,
or Tonga, but all other centres detected some
gonococci of this type. The proportion of
TRNG seen in Vietnam increased significantly
(p < 0.05) over the survey period.
SUSCEPTIBILITY TO THIRD GENERATION
CEPHALOSPORINS
No clinical resistance to the third generation
cephalosporins has yet been reported.
However, the programme monitored sensitiv-
ity to ceftriaxone in nine centres in 1992, 1 1 in
1993 and 10 in 1994, examining a total of
9544 isolates in the 3 years (table 5). The lack
of definition of precise breakpoints for ceftri-
axone resistance and the absence of confirmed
clinical resistance precludes comment on
"resistance" to this group of agents. Some
centres also tested other agents used in their
locality and resistance to kanamycin (Malaysia
and Vietnam) and chloramphenicol (Vietnam)
was recorded.
The results of the proficiency testing pro-
gramme using reference QC and QA cultures
revealed a satisfactory level of participant per-
formance with over 95% of examinations plac-
ing the QC and QA cultures in the correct
category. Some problems with testing of indi-
vidual antibiotics were detected in some cen-
tres early in the programme. Data from these
sources were not included until problems were
resolved. Strains from one contributing labo-
ratory were referrred to the regional reference
centre for testing in the absence of suitable
facilities in that country.
Table 5 Number of isolates testedfor ceftriaxone susceptibility in 13 WPRO GASP
centres, 1992-4
No tested
Country 1992 1993 1994
Australia 782 1570 1622
Brunei 20 40 0
China 109 0 151
Fiji 0 24 804
Hong Kong 0 1041 0
Japan 145 57 83
Korea 43 225 192
Malaysia 185 280 148
New Caledonia 40 0 0
Papua New Guinea 0 40 218
Sinagapore 130 568 667
Solomon Islands 0 15 20
Vietnam 19 115 215
Discussion
Considerable progress has been made in the
area of organised surveillance of antimicrobial
susceptibility of gonococci in the WHO
WPRO in the past few years. In this period
country based networks have been expanded
or established and these have coalesced into a
coherent regional programme. The region
contains highly developed nations, countries
with emerging economies, small Pacific Island
states, and underdeveloped areas all of which
have contributed validated data to what is now
a continuing long term surveillance pro-
gramme. In order to reconcile the differences
in susceptibility testing technique and capabil-
ities of the different participants, a pragmatic
approach was adopted which utilised existing
resources and accepted data from sources
which were limited to P lactamase testing with
disc screening methods to full agar incorpora-
tion techniques. The variations in methodol-
ogy in place at the beginning of the
programme were reduced by nominating test
methods and a quality assurance and quality
control programme further overcame effects
caused by remaining differences and allowed
comparison and validation of data.'2
The programme expanded in terms of sam-
ple size and coverage in the period under
review, but the sample base in most instances
was from similar sources-namely, unselected
symptomatic patients. As the programme set-
tled into a regular pattern, the advantages of
longitudinal surveillance, as opposed to point
prevalence examinations, became more obvi-
ous. The longer term nature of the programme
helped to mitigate any effect of possible selec-
tion bias resulting from use of a restricted
sample base. While it is acknowledged that
different groups of patients may be infected
with gonococci with different sensitivity pat-
terns-for example, urban and rural, if the
source of isolates under surveillance remains
relatively constant, alterations in the pattern of
sensitivity within that cohort can be validly
detected over time and this will provide an
indication of shifts in gonococcal susceptibil-
ity.
Changes in antibiotic resistance patterns
were evident in this study particularly within
the quinolone group of antibiotics. In the
period of this study, quinolone resistant gono-
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cocci appeared in more centres, in a higher
proportion of isolates in those centres, and at
increasingly high MIC levels. While it was for-
tuitous that the programme was operating at
the time when these strains were appearing, it
was reassuring that the programmme was able
not only to detect these important trends but
to also give an assessment of the rapidity and
extent of this change. In some centres-for
example, Hong Kong, and the Philippines,
quinolone resistant gonococci have become
endemic while in others (Australia, New
Zealand) most isolates of this type are from
infected travellers and secondary spread of
quinolone resistant gonococci is as yet limited.
The observations on quinolone resistance
made in the WPRO programme would appear
to have been confirmed by other reports of
quinolone resistance in isolates from travellers
returning to their home country after acquir-
ing infections in the WPR. These reports indi-
cate that the infections were acquired in those
parts of the WPR where high levels of
quinolone resistance were observed in this
study2'-26 and reveal the significance of emerg-
ing quinolone resistance on countries outside
the WPR. A number of clusters of cases have
been identified22 24 and treatment recommen-
dations for travellers infected in WPR coun-
tries have been modified.24 26
Fewer changes were noted in the regional
patterns of resistance to the other core antimi-
crobials tested. There were however marked
differences in the various parts of the region in
terms of resistance to the individual antimicro-
bials, reflecting the diverse nature of antibiotic
usage and availability and different economic
conditions in the WPRO GASP participant
countries. Although the penicillins are little
used because of resistance to them, the spread
of PPNG in China and Vietnam and the
decline of PPNG in Hong Kong are examples
of changes occurring over time in parts of the
region. In China and Vietnam the increases
could be ascribed to the more frequent inter-
national travel in these countries. The
decrease in PPNG in Hong Kong has been
explained by the prolonged use of quinolone
antibiotics.27 Additionally, the higher rates of
TRNG in Singapore and Malaysia reflect a
more stable geographic variation. However,
the WHO WPRO is a region where gonococ-
cal resistance to a number of antibiotics has
emerged previously, the appearance of PPNG
and spectinomycin resistant strains being two
examples. The availability of certain antibi-
otics and the consequent potential for their
misuse has no doubt contributed to this situa-
tion in the past. However, resistant gonococci
are seldom restricted to a particular geo-
graphic region for long, and the appearance of
resistance to one or more antibiotics in this
region will see spread of these isolates to more
distant localities by infected travellers, as has
occurred with the quinolone resistant strains.
In this context it is important to continue to
monitor antibiotic resistance in gonococci in
WPRO so as to be aware of potential difficulties
with therapy as they arise and in a wider than
local context.
In addition to obtaining information on
gonococcal susceptibility to contribute to a
global programme, one aim of the project is to
help construct or modify appropriate treatment
regimens for gonococcal disease in the partici-
pating countries themselves. It is known and
also evident from this study and others that
there are considerable temporal and geographic
variations in gonococcal susceptibilty patterns.
This means that surveillance programmes and
the treatment regimens based upon them must
be attuned to local needs while maintaining an
awareness of changes elsewhere that may
impinge on the effectiveness of local measures.
This programme initially attempted to have a
quarterly reporting period to maximise dissem-
ination of data, but it soon became evident that
this was not practical given the number of par-
ticipants who, in some instances, themselves
collated results from other centres. The timeli-
ness ofnew or changing information was there-
fore enhanced by the individual centres making
their local information available to relevant
bodies in their locale as well as reporting it to
the central system. The information produced
by WPRO GASP has been positively applied in
the region. Some options for cheap oral treat-
ment of gonorrhoea-penicillins and tetracy-
clines-have been greatly reduced in the region
because of resistance, and even relatively
expensive therapies such as quinolones are
becoming less effective. Other antibiotics, even
if more expensive in terms of unit cost, have
longer term benefits as ineffective cheaper ther-
apies neither treat the individual adequately
nor prevent complications or spread of the
organism to others. The findings of this surveil-
lance programme have been fundamental to
the establishment of a recommended treatment
regimen in some countries (for example,
Australia, Papua New Guinea, Solomon
Islands) and for the modification or reassur-
ance of effectiveness of recommendations in
others (New Caledonia). Paradoxically some
older agents remain useful in some settings.
Spectinomycin resistance is now uncommon,
perhaps because its use has declined in recent
years, but it is expensive and requires adminis-
tration by injection.
Cephalosporins, whether oral or injectable,
retain their usefulness but their cost makes
them difficult to introduce in some circum-
stances. Additionally, some of the oral third
generation cephalosporins are administered in
a lower dose equivalent than the injectable
agents formerly used, and this, together with
the potential for misuse or inappropriate
dosing of oral agents means that the
cephalosporin sensitivity of gonococci should
be closely monitored. The WPRO GASP has
contributed significant information thus far,
but will need to maintain and perhaps extend
surveillance as newer agents are introduced.
The programme also aims to improve stan-
dards of technical performance and this has
occurred by a number of means in the life of
the programme. It would thus appear that
other considerable benefits, often intangible,
have also accrued in this area since the pro-
gramme's inception.
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